Resolvin D1 Shows Protective Effects Against Alcohol-Related Liver Damage in Mice
This animal study looked at a lipid molecule called resolvin D1 (RvD1), which the body naturally produces to help resolve inflammation. Researchers created a mouse model of severe alcohol-associated liver disease by combining chronic ethanol feeding with a liver-sensitizing chemical called galactosamine, followed by an alcohol binge.
This combination caused significant liver injury, inflammation, early fibrosis-related gene changes, and a reduced ability of the liver to regenerate — mimicking features seen in advanced alcohol-related liver disease in humans.
When mice were treated with RvD1 before and during the injury model, they showed lower blood endotoxin and liver enzyme (ALT) levels, less liver tissue death, and fewer inflammatory immune cells in the liver. RvD1 also reduced certain inflammatory markers, dampened pro-fibrotic gene activity, and helped restore some liver regeneration and protein production (albumin) that alcohol exposure had impaired.
What this means for you
This is early-stage mouse research, not a human study, so it doesn’t tell us whether resolvin D1 or omega-3 fatty acids (which the body can convert into resolvins) would have the same effect in people with liver disease. It does add to a growing body of evidence suggesting that specialized lipid mediators derived from fatty acids may play a role in how the body manages inflammation and tissue repair, including in the liver.
Ready to start? The ALP Protocol delivers the EPA & DHA doses used in the research.
Start the ALP ProtocolSource
Hepatology communications · 2026-09-01 · DOI: 10.1097/HC9.0000000000001039
Read the original source ↗This summary is for educational purposes only and is not medical advice. Always talk to your healthcare provider before making changes to your supplement routine.